Unitaid, a part of the WHO, engaged the UW’s TLC-ART program for developing a grant agreement (GAD). It intends to accelerate the global impact of long-acting (LA) HIV medicines enabled by TLC-ART innovations. The project will transform current oral drugs into more effective, targeted LA therapies to improve patient appeal.
Follow this link for additional information: Unitaid Resolution 14-2019-e